Jazz Pharmaceuticals plc (JAZZ) Stock Forecast
Data as of Aug 1, 2026Healthcare · Current price $253.08 (-2.08%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Mar 9, 2026 | Etzer Darout | Barclays | $224.00 | -11.5% |
| Jan 12, 2026 | Ami Fadia | Needham | $235.00 | -7.1% |
| Jan 8, 2026 | Sean Laaman | Morgan Stanley | $225.00 | -11.1% |
| Dec 10, 2025 | David Amsellem | Piper Sandler | $219.00 | -13.5% |
| Nov 24, 2025 | Ashwani Verma | UBS | $188.00 | -25.7% |
| Nov 17, 2025 | Sean Laaman | Morgan Stanley | $205.00 | -19.0% |
| Aug 28, 2025 | Joon Lee | Truist Financial | $205.00 | -19.0% |
| Aug 28, 2025 | Gregory Renza | RBC Capital | $151.00 | -40.3% |
| Jul 15, 2025 | David Hoang | Deutsche Bank | $152.00 | -39.9% |
| Feb 27, 2025 | Balaji Prasad | Barclays | $200.00 | -21.0% |
| Nov 21, 2024 | Akash Tewar | Jefferies | $160.00 | -36.8% |
| Nov 18, 2024 | Joel Beatty | Robert W. Baird | $162.00 | -36.0% |
| Oct 23, 2024 | Daniel Busb | RBC Capital | $179.00 | -29.3% |
| Sep 11, 2024 | Annabel Samimy | Stifel Nicolaus | $230.00 | -9.1% |
| Jun 5, 2024 | Andrea Tan | Goldman Sachs | $169.00 | -33.2% |
| May 2, 2024 | Daniel Busb | RBC Capital | $176.00 | -30.5% |
| Mar 20, 2024 | David Amsellem | Piper Sandler | $188.00 | -25.7% |
| Jun 20, 2022 | David Amsellem | Piper Sandler | $193.00 | -23.7% |
| Jun 13, 2022 | Ashwani Verma | UBS | $194.00 | -23.3% |
| Mar 3, 2022 | Ami Fadia | Needham | $215.00 | -15.0% |
Top Analysts Covering JAZZ
JAZZ vs Sector & Market
| Metric | JAZZ | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.25 | 2.42 |
| Analyst Count | 21 | 8 | 19 |
| Target Upside | +5.3% | +16316.2% | +17.1% |
| P/E Ratio | 2300.73 | 0.87 | 43.33 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $1.14B | $1.16B | $1.19B | 5 |
| 2026-12-31 | $1.18B | $1.20B | $1.23B | 5 |
| 2027-03-31 | $1.01B | $1.03B | $1.06B | 5 |
| 2027-06-30 | $1.16B | $1.18B | $1.22B | 5 |
| 2027-09-30 | $1.23B | $1.26B | $1.29B | 5 |
| 2027-12-31 | $1.30B | $1.33B | $1.36B | 5 |
| 2028-12-31 | $5.18B | $5.19B | $5.21B | 13 |
| 2029-12-31 | $5.59B | $5.75B | $5.95B | 12 |
| 2030-12-31 | $5.81B | $5.98B | $6.18B | 6 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $6.27 | $6.42 | $6.65 | 7 |
| 2026-12-31 | $6.82 | $6.98 | $7.23 | 4 |
| 2027-03-31 | $4.67 | $4.78 | $4.96 | 4 |
| 2027-06-30 | $5.92 | $6.07 | $6.28 | 5 |
| 2027-09-30 | $6.66 | $6.82 | $7.06 | 8 |
| 2027-12-31 | $7.10 | $7.27 | $7.53 | 4 |
| 2028-12-31 | $19.04 | $28.27 | $40.18 | 5 |
| 2029-12-31 | $29.95 | $31.05 | $32.41 | 1 |
| 2030-12-31 | $31.00 | $32.14 | $33.55 | 1 |
Frequently Asked Questions
What is the analyst consensus for JAZZ?
The consensus among 21 analysts covering Jazz Pharmaceuticals plc (JAZZ) is Buy with an average price target of $257.44.
What is the highest price target for JAZZ?
The highest price target for JAZZ is $250.00, set by Balaji Prasad at Barclays on 2021-06-22.
What is the lowest price target for JAZZ?
The lowest price target for JAZZ is $151.00, set by Gregory Renza at RBC Capital on 2025-08-28.
How many analysts cover JAZZ?
21 analysts have issued ratings for Jazz Pharmaceuticals plc in the past 12 months.
Is JAZZ a buy or sell right now?
Based on 21 analyst ratings, JAZZ has a consensus rating of Buy (2.00/5) with a +5.3% upside to the consensus target of $257.44.
What are the earnings estimates for JAZZ?
Analysts estimate JAZZ will report EPS of $6.42 for the period ending 2026-09-30, with revenue estimated at $1.16B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.